Carcinoma, Non-Small-Cell Lung: all 6,641 studies

Page 18 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.

• Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)CompletedNCT05259696Phase 1/2Results posted
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsTerminatedNCT05256381Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationCompletedNCT05253807Phase 2Results posted
• The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic SurgeryTerminatedNCT05251805Not applicableResults posted
• Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Phase 3Results posted
• Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).CompletedNCT05219162Phase 4Results posted
• Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung CancerCompletedNCT05212285Results posted
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsTerminatedNCT05194735Phase 1/2Results posted
• A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung CancerCompletedNCT05171777Phase 2Results posted
• A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung CancerTerminatedNCT05141357Phase 2Results posted
• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 4Results posted
• A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersTerminatedNCT05091528Phase 1/2Results posted
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05089734Phase 3Results posted
• IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCCompletedNCT05077709Phase 2Results posted
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTerminatedNCT05070247Phase 1/2Results posted
• Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedNCT05054725Phase 2Results posted
• Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerCompletedNCT05014815Phase 2Results posted
• A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCompletedNCT05005273Phase 2Results posted
• A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid TumorsCompletedNCT05001347Phase 2Results posted
• A Study of SEA-CD40 Given With Other Drugs in CancersCompletedNCT04993677Phase 2Results posted
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Phase 3Results posted
• Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsTerminatedNCT04985604Phase 2Results posted
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCTerminatedNCT04984811Phase 2Results posted
• Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese PatientsCompletedNCT04979988Results posted
• Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain MetastasesCompletedNCT04967417Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)CompletedNCT04956692Phase 3Results posted
• A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentTerminatedNCT04933695Phase 2Results posted
• Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCTerminatedNCT04926831Phase 2Results posted
• Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCTerminatedNCT04925986Phase 2Results posted
• Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Phase 3Results posted
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results posted
• A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)TerminatedNCT04914897Phase 2Results posted
• Ruxolitinib for Cancer CachexiaActive, not recruitingNCT04906746Early Phase 1Results posted
• NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLCCompletedNCT04880863Phase 2Results posted
• A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersCompletedNCT04879849Phase 1Results posted
• A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerTerminatedNCT04866017Phase 3Results posted
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)TerminatedNCT04863248Phase 2Results posted
• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsCompletedNCT04853017Phase 1Results posted
• A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerTerminatedNCT04844073Phase 1/2Results posted
• Alvopem® (Pemetrexed) Safety AssessmentCompletedNCT04843007Results posted
• A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung CancerTerminatedNCT04832854Phase 2Results posted
• Study of AMG 160 in Subjects With Non-Small Cell Lung CancerTerminatedNCT04822298Phase 1Results posted
• Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI TreatmentTerminatedNCT04820023Phase 1/2Results posted
• Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedNCT04816214Phase 3Results posted
• Intratumoral Cisplatin for Resectable NSCLCCompletedNCT04809103Phase 1Results posted
• Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung AdenocarcinomaCompletedNCT04795245Results posted
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedNCT04789668Phase 1/2Results posted
• Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLCTerminatedNCT04786964Phase 3Results posted
• Durvalumab and Stereotactic Radiotherapy for Advanced NSCLCTerminatedNCT04786093Phase 2Results posted
• Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)CompletedNCT04776447Phase 2Results posted
• Molecular Disease Characterization Initiative (MDCI)TerminatedNCT04772053Phase 2Results posted
• A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04765059Phase 3Results posted
• Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.CompletedNCT04750824Results posted
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Phase 3Results posted
• Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedNCT04738487Phase 3Results posted
• Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompletedNCT04735068Phase 2Results posted
• Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)CompletedNCT04725188Phase 2Results posted
• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive, not recruitingNCT04685135Phase 3Results posted
• [18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer PatientsCompletedNCT04678440Early Phase 1Results posted
• Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationCompletedNCT04677595Phase 2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension StudyCompletedNCT04676412Phase 3Results posted
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active, not recruitingNCT04656652Phase 3Results posted
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyActive, not recruitingNCT04655976Phase 2/3Results posted
• Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT04644237Phase 2Results posted
• Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.CompletedNCT04642469Phase 3Results posted
• Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung CancerTerminatedNCT04639245Phase 1/2Results posted
• A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)CompletedNCT04623775Phase 2Results posted
• A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung CancerCompletedNCT04619797Phase 2/3Results posted
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive, not recruitingNCT04606771Phase 2Results posted
• Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryTerminatedNCT04588246Phase 3Results posted
• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedNCT04585815Phase 1/2Results posted
• Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)TerminatedNCT04581824Phase 2Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung CancerTerminatedNCT04560686Phase 2Results posted
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementTerminatedNCT04543188Phase 1Results posted
• Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaCompletedNCT04541706Phase 4Results posted
• A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsActive, not recruitingNCT04538664Phase 3Results posted
• Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04533451Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04513925Phase 3Results posted
• Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsTerminatedNCT04512430Phase 2Results posted
• Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsCompletedNCT04511533Phase 4Results posted
• Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell CarcinomaTerminatedNCT04495894Phase 2Results posted
• FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic RadiotherapyTerminatedNCT04491084Phase 1/2Results posted
• A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Phase 3Results posted
• Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)CompletedNCT04484142Phase 2Results posted
• Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLCTerminatedNCT04476797Phase 1/2Results posted
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung CancerCompletedNCT04475939Phase 3Results posted
• Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyCompletedNCT04471428Phase 3Results posted
• A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCompletedNCT04452877Phase 2Results posted
• Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLCTerminatedNCT04441138Phase 2Results posted
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationTerminatedNCT04427072Phase 3Results posted
• A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerCompletedNCT04426825Phase 2Results posted
• Study of Poziotinib in Japanese Patients With NSCLCTerminatedNCT04402008Phase 1/2Results posted
• Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer PatientsTerminatedNCT04398199Phase 2Results posted
• Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)TerminatedNCT04394624Phase 2Results posted
• Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)CompletedNCT04385368Phase 3Results posted
• Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor MalignanciesCompletedNCT04383938Phase 1/2Results posted
• ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-ImmunotherapyTerminatedNCT04372927Phase 2Results posted
• AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)CompletedNCT04364620Phase 2Results posted

← Carcinoma, Non-Small-Cell Lung overview